-
-
Small Molecule Drug Platforms
-
Chiral Catalysis Technology
-
Continuous Flow Technology
-
Fluorine Chemistry
-
Enzyme Catalysis
-
Photocatalysis
-
Solid-State Research
显示更多 -
-
Drug Product (DP) Platforms
-
Sustained and Controlled Release
-
Solubility Enhancement
-
Topical Formulation
-
Liquid Formulation
-
Softgels
-
Oral Fast Dissolving Technology
显示更多 -
-
Peptide Platforms
显示更多 -
Research Team
-
Peptide API Manufacturing: Building Industrialization Capabilities for High-Quality Peptide APIs
Release time:
2025-12-15
With continuous breakthroughs in peptide-based drugs in the treatment of chronic diseases, cancer, and metabolic disorders, Peptide API Manufacturing has become one of the fastest-growing segments in the global pharmaceutical industry. Peptide APIs are characterized by their complex structure, bioactivity sensitivity, and high quality requirements, demanding higher standards for the technical platforms and quality systems of manufacturing companies.

In the peptide API manufacturing process, every step-from amino-acid raw material qualification and control and synthesis route design to purification, analysis, and scale-up production, can directly impact the safety and consistency of the final product. Mature peptide manufacturing capabilities require not only mastery of solid-phase and liquid-phase synthesis technologies but also systematic solutions in high-purity separation, impurity control, and stability studies.
At the same time, as clinical projects progress to later stages and commercial production scales up, higher demands are placed on the scalability and supply stability of peptide API production. Companies with advanced technical platforms can achieve smooth scale-up from gram-scale and kilogram-scale to commercial scale while ensuring quality compliance.
Through continuous process optimization and quality management system development, advanced Peptide API Manufacturing capabilities are providing reliable support to global pharmaceutical companies, accelerating the transition of innovative peptide drugs from the research and development stage to commercial application, and providing patients with safer and more effective treatment options.
Other News
2026-11-10
Winter Process Chemistry Conference
2026-11-03
2026-11-03
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Business Collaboration
Innovative Drug CDMO Services
Tel: 86-576-85588039 / 86-576-85580090
E-mail: bd@jiuzhoupharma.com
Established Business Services(API)
Tel: 86-576-88881561
E-mail: bd@jiuzhoupharma.com